AI assistant
MYRIAD GENETICS INC — Director's Dealing 2026
Feb 27, 2026
32566_dirs_2026-02-27_9fd75143-d826-49f8-ac1e-e4edfe8c9d1c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: MYRIAD GENETICS INC (MYGN)
CIK: 0000899923
Period of Report: 2026-02-25
Reporting Person: Phanstiel S. Louise (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-02-25 | Common Stock | P | 6100 | $4.736 | Acquired | 183544 | Direct |
| 2026-02-26 | Common Stock | P | 50407 | $4.803 | Acquired | 233951 | Direct |
| 2026-02-27 | Common Stock | P | 48000 | $4.661 | Acquired | 281951 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 33119 | Indirect |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.725 to $4.75, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.71 to $5.01, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.51 to $4.79, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.